SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.16% of ...

Preliminary, unaudited revenue for the full year 2024 of approximately $174 millionPresenting at the 43rd Annual J.P. Morgan Healthcare ...

The SpinCo will be focused on building a pipeline of innovative medicines with robust clinical proof-of-concept in oncology, immunology, and/or virology through strategic business development ...

Standard BioTools reports preliminary 2024 revenue of $174 million and will present at the J.P. Morgan Healthcare Conference. Standard BioTools Inc. announced preliminary, unaudited revenue ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced ...

‘THE NETWORK OF RECORD‘ Lazarus, chief executive of the new company for now named SpinCo, gave a striking vote of confidence for Golf Channel in an interview with SBJ’s Josh Carpente ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a ...

In recent trading, Standard Biotools Inc (LAB) stock price has shown some volatility, fluctuating 13.19% over the last five trades and 1 ...

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results ...